Print Page      Close Window

Investor Overview


Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA, and PRIME (PRIority MEdicines) designation by the European Medicines Agency.
NASDAQ GS TOCA (Common Stock)
$9.38 + 0.18
Stock chart for: TOCA.O.  Currently trading at $9.38 with a 52 week high of $14.66 and a 52 week low of $8.31.
07/20/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Tocagen Closes Previously Announced License Agreement with ApolloBio to Develop and Commercialize Toca 511 & Toca FC in Greater China

07/09/18

Read More

Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

05/14/18

Read More

Tocagen Reports First Quarter 2018 Financial and Business Results

05/10/18

Read More

Recent Presentation

View All  
DateTitle
06/28/18
Download Documentation Corporate Presentation – June 2018
05/21/18
Download Documentation Toca 511 & Toca FC: Evaluation of durable response rate in the post-resection setting and association with survival in patients with recurrent high grade glioma

Upcoming Events

View All  
There are currently no events scheduled.